Jiuyuan Gene Completes H-Share Full Circulation, Converts 136.30 Million Unlisted Shares

Bulletin Express05-14

Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd. (Jiuyuan Gene) announced the formal completion of its H-share full-circulation plan. On 14 May 2026, 136.30 million previously unlisted domestic shares were converted into H shares, with trading set to commence on the Hong Kong Stock Exchange at 9:00 a.m. on 15 May 2026.

Following the conversion, the company’s entire issued share capital of 245.40 million shares is now fully tradable as H shares. Prior to the move, H shares totaled 109.10 million, representing 44.5 % of the share base, while 136.30 million shares (55.5 %) remained unlisted. Post-conversion, Jiuyuan Gene’s H-share count has risen to 245.40 million, equivalent to 100 % of the company’s issued shares.

The milestone follows a series of regulatory approvals: shareholder endorsement on 22 December 2025, a filing notice from the China Securities Regulatory Commission on 2 April 2026, and listing approval from the Hong Kong Stock Exchange on 8 May 2026.

Management advises shareholders and potential investors to exercise caution when dealing in the company’s shares.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1164972787?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-14 20:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1164972787","market":"hk","top_or_hot":-1,"title":"Jiuyuan Gene Completes H-Share Full Circulation, Converts 136.30 Million Unlisted Shares","media":"Bulletin Express","content":"<p>Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd. (Jiuyuan Gene) announced the formal completion of its H-share full-circulation plan. On 14 May 2026, 136.30 million previously unlisted domestic shares were converted into H shares, with trading set to commence on the Hong Kong Stock Exchange at 9:00 a.m. on 15 May 2026.</p>\n<p>Following the conversion, the company’s entire issued share capital of 245.40 million shares is now fully tradable as H shares. Prior to the move, H shares totaled 109.10 million, representing 44.5 % of the share base, while 136.30 million shares (55.5 %) remained unlisted. Post-conversion, Jiuyuan Gene’s H-share count has risen to 245.40 million, equivalent to 100 % of the company’s issued shares.</p>\n<p>The milestone follows a series of regulatory approvals: shareholder endorsement on 22 December 2025, a filing notice from the China Securities Regulatory Commission on 2 April 2026, and listing approval from the Hong Kong Stock Exchange on 8 May 2026.</p>\n<p>Management advises shareholders and potential investors to exercise caution when dealing in the company’s shares.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Jiuyuan Gene Completes H-Share Full Circulation, Converts 136.30 Million Unlisted Shares</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJiuyuan Gene Completes H-Share Full Circulation, Converts 136.30 Million Unlisted Shares\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-05-14 20:03</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd. (Jiuyuan Gene) announced the formal completion of its H-share full-circulation plan. On 14 May 2026, 136.30 million previously unlisted domestic shares were converted into H shares, with trading set to commence on the Hong Kong Stock Exchange at 9:00 a.m. on 15 May 2026.</p>\n<p>Following the conversion, the company’s entire issued share capital of 245.40 million shares is now fully tradable as H shares. Prior to the move, H shares totaled 109.10 million, representing 44.5 % of the share base, while 136.30 million shares (55.5 %) remained unlisted. Post-conversion, Jiuyuan Gene’s H-share count has risen to 245.40 million, equivalent to 100 % of the company’s issued shares.</p>\n<p>The milestone follows a series of regulatory approvals: shareholder endorsement on 22 December 2025, a filing notice from the China Securities Regulatory Commission on 2 April 2026, and listing approval from the Hong Kong Stock Exchange on 8 May 2026.</p>\n<p>Management advises shareholders and potential investors to exercise caution when dealing in the company’s shares.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02566","symbol_name":"九源基因","start_time":0,"source_url":"","article_id":"1164972787","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1164972787","pubTimestamp":1778760194,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd. (Jiuyuan Gene) announced the formal completion of its H-share full-circulation plan. On 14 May 2026, 136.30 million previously unlisted domestic...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02566":"九源基因"},"translate_title":"玖源基因完成H股全流通，转换未上市股份1.363亿股","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02566":1},"content_text":"Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd. (Jiuyuan Gene) announced the formal completion of its H-share full-circulation plan. On 14 May 2026, 136.30 million previously unlisted domestic shares were converted into H shares, with trading set to commence on the Hong Kong Stock Exchange at 9:00 a.m. on 15 May 2026.\nFollowing the conversion, the company’s entire issued share capital of 245.40 million shares is now fully tradable as H shares. Prior to the move, H shares totaled 109.10 million, representing 44.5 % of the share base, while 136.30 million shares (55.5 %) remained unlisted. Post-conversion, Jiuyuan Gene’s H-share count has risen to 245.40 million, equivalent to 100 % of the company’s issued shares.\nThe milestone follows a series of regulatory approvals: shareholder endorsement on 22 December 2025, a filing notice from the China Securities Regulatory Commission on 2 April 2026, and listing approval from the Hong Kong Stock Exchange on 8 May 2026.\nManagement advises shareholders and potential investors to exercise caution when dealing in the company’s shares.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.3","shortVersion":"4.42.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1164972787","isCrawlerRequest":true}